Products
Platform
Research
Market
Learn
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹500 | - |
Expense Ratio | 2.37 | - |
NAV | ₹9.81 | - |
Fund Started | 06 Dec 2024 | - |
Fund Size | ₹335.88 Cr | - |
Exit Load | 1% for redemption within 3 Months | - |
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹500
-
Expense Ratio
2.37
-
NAV
₹9.81
-
Fund Started
06 Dec 2024
-
Fund Size
₹335.88 Cr
-
Exit Load
1% for redemption within 3 Months
-
Returns
1 Year | - | - |
3 Year | - | - |
5 Year | - | - |
1 Year
-
-
3 Year
-
-
5 Year
-
-
Holding Analysis
Equity | 95.81% | - |
Cash | -0.19% | - |
Equity
95.81%
-
Cash
-0.19%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
Divi's Laboratories Ltd. | 8.81% |
Sun Pharmaceutical Industries Ltd. | 7.66% |
Apollo Hospitals Enterprise Ltd. | 6.26% |
Cipla Ltd. | 5.00% |
Neuland Laboratories Ltd. | 4.09% |
Biocon Ltd. | 3.76% |
Fortis Healthcare Ltd. | 3.66% |
Aurobindo Pharma Ltd. | 3.48% |
Piramal Pharma Ltd. | 3.24% |
Emcure Pharmaceuticals Ltd. | 3.22% |
-
Fund Manager
Name | Sorbh Gupta | - |
Start Date | 10 Nov 2025 | - |
Name
Sorbh Gupta
-
Start Date
10 Nov 2025
-
About Fund
Description | The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies. | - |
Launch Date | 06 Dec 2024 | - |
Description
The Scheme seeks to generate long term capital appreciation by predominantly investing in equity and equity related securities of pharma, healthcare and allied companies.
-
Launch Date
06 Dec 2024
-